[109] In addition, a phase II study demonstrated the efficacy of everolimus in previously treated patients with advanced GC.[152] Recent studies have found that everolimus can improve the chemosensitivity of GC by targeting the METTL3/miR-17-92/TMEM127 or PTEN/ mTOR signaling pathways. Here, MTOR is linked to gastric cancer.